Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
A phase 1/2 trial of Pembrolizumab in triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma, run by Scancell Ltd, now recruiting.
Overview
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer is a phase 1/2 interventional study registered as NCT05329532 by Scancell Ltd, with 168 participants planned, started 2022-04-07 and due to reach its primary completion in 2026-07-01. Interventions recorded: Modi-1 Moditope, Pembrolizumab and MicronJet600™ microneedle device (NanoPass).
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Shares Renal cell carcinoma, Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Scancell and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
- TrialSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Renal cell carcinoma, Ovarian cancer and the tag pipeline.